Scholarlink

<p>A series of novel 2-(chloromethyl)-5-(pyridin-4-yl)-1,3,4-oxadiazole (3a-h) derivatives have been synthesized as potential anti-TB, antioxidant, and COX inhibitors. The structure of these derivatives is confirmed by the IR, NMR (<sup>1</sup>H and <sup>13</sup>C), and mass spectral analysis. All the newly synthesized derivatives were evaluated for their physicochemical properties by Swiss ADME. Based on our previous work and structural activity relationship study, foresaid isoniazid derivatives were evaluated for in vitro anti-TB, antioxidant, and COX inhibitory activity. The compound 3f exhibited outstanding anti-TB activity with a MIC value of 0.8&#xa0;μg/mL. The compounds 3d, 3f, and 3h proved promising antioxidant activity at a concentration of 10&#xa0;μg/ml with inhibition rates of 66.12%, 67.59%, and 66.28%, respectively. The compounds 3e, 3f, and 3h established excellent COX-I inhibitions with IC<sub>50</sub> values of 4.21, 3.24, and 4.89&#xa0;μM compared to standard drugs. Finally, the molecular docking studies carried out with <i>Mycobacterium tuberculosis</i> enoyl reductase (INHA) complexed with 1-cyclohexyl-<i>N</i>-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide (PDB ID: 4TZK), cytochrome c peroxidase (PDB ID: 2X08), and cyclooxygenase-2 (PDB ID: 6COX) for all the newly synthesized derivatives.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploration of novel isoniazid embedded 1,3,4-oxadiazole hybrids as anti-TB, antioxidant, and COX inhibitors: synthesis, spectral analysis, and molecular modeling studies

  • 期刊论文

  • 发表日期：

    2025年1月29日

查看全文
  • S. P. Jisha,
  • G. Y. Nagesh,
  • Prashantha Karunakar,
  • G. Nidhi,
  • B. T. Sridhar,
  • S. M. Basavarajaiah

摘要

A series of novel 2-(chloromethyl)-5-(pyridin-4-yl)-1,3,4-oxadiazole (3a-h) derivatives have been synthesized as potential anti-TB, antioxidant, and COX inhibitors. The structure of these derivatives is confirmed by the IR, NMR (1H and 13C), and mass spectral analysis. All the newly synthesized derivatives were evaluated for their physicochemical properties by Swiss ADME. Based on our previous work and structural activity relationship study, foresaid isoniazid derivatives were evaluated for in vitro anti-TB, antioxidant, and COX inhibitory activity. The compound 3f exhibited outstanding anti-TB activity with a MIC value of 0.8 μg/mL. The compounds 3d, 3f, and 3h proved promising antioxidant activity at a concentration of 10 μg/ml with inhibition rates of 66.12%, 67.59%, and 66.28%, respectively. The compounds 3e, 3f, and 3h established excellent COX-I inhibitions with IC50 values of 4.21, 3.24, and 4.89 μM compared to standard drugs. Finally, the molecular docking studies carried out with Mycobacterium tuberculosis enoyl reductase (INHA) complexed with 1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide (PDB ID: 4TZK), cytochrome c peroxidase (PDB ID: 2X08), and cyclooxygenase-2 (PDB ID: 6COX) for all the newly synthesized derivatives.

Graphical abstract